UniProtKB/Swiss-Prot P07992 : Variant p.Phe231Leu
DNA excision repair protein ERCC-1
Gene: ERCC1
Feedback ?
Variant information
Variant position:
231
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Phenylalanine (F) to Leucine (L) at position 231 (F231L, p.Phe231Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and aromatic (F) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In COFS4; does not alter interaction with ERCC4/XPF.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
231
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
297
The length of the canonical sequence.
Location on the sequence:
TYKAYEQKPADLLMEKLEQD
F VSRVTECLTTVKSVNKTDSQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TYKAYEQKPADLLMEK---LEQDF VSRVTECLTTVKSVNKTDSQ
Mouse TYKAYEQKPADLLMEK---LEQNF LSRATECLTTVKSVNKT
Bovine TYKAYEQKPADLLMEK---LEQDF VSRVTECLTTVKSVNKT
Slime mold AYKTFNNRAPDPIKARAQPIELGG KSKNEQVLTSIKSVNKT
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 297
DNA excision repair protein ERCC-1
Region
220 – 297
HhH2, dimerization with ERCC4/XPF
Cross
243 – 243
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Mutagenesis
221 – 221
D -> A. Impaired interaction with ERCC4.
Mutagenesis
223 – 223
L -> A. Impaired interaction with ERCC4.
Mutagenesis
224 – 224
M -> A. Impaired interaction with ERCC4.
Mutagenesis
225 – 225
E -> A. Impaired interaction with ERCC4.
Mutagenesis
227 – 227
L -> A. Impaired interaction with ERCC4.
Mutagenesis
228 – 228
E -> A. Impaired interaction with ERCC4.
Literature citations
First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure.
Jaspers N.G.J.; Raams A.; Silengo M.C.; Wijgers N.; Niedernhofer L.J.; Robinson A.R.; Giglia-Mari G.; Hoogstraten D.; Kleijer W.J.; Hoeijmakers J.H.J.; Vermeulen W.;
Am. J. Hum. Genet. 80:457-466(2007)
Cited for: VARIANT COFS4 LEU-231; CHARACTERIZATION OF VARIANT COFS4 LEU-231; FUNCTION; SUBUNIT;
Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia.
Kashiyama K.; Nakazawa Y.; Pilz D.T.; Guo C.; Shimada M.; Sasaki K.; Fawcett H.; Wing J.F.; Lewin S.O.; Carr L.; Li T.S.; Yoshiura K.; Utani A.; Hirano A.; Yamashita S.; Greenblatt D.; Nardo T.; Stefanini M.; McGibbon D.; Sarkany R.; Fassihi H.; Takahashi Y.; Nagayama Y.; Mitsutake N.; Lehmann A.R.; Ogi T.;
Am. J. Hum. Genet. 92:807-819(2013)
Cited for: VARIANT COFS4 LEU-231; CHARACTERIZATION OF VARIANT COFS4 LEU-231; FUNCTION; INTERACTION WITH ERCC4;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.